Cargando…

Central Nervous System Metastasis in Neuroblastoma: From Three Decades Clinical Experience to New Considerations in the Immunotherapy Era

SIMPLE SUMMARY: Central nervous system (CNS) metastatic spread in neuroblastoma (NB) is rare and occurs more often at relapse/progression. In this retrospective study, we reviewed the CNS imaging of all the patients treated at the Bambino Gesù Children Hospital over a 25-year period. CNS metastasis...

Descripción completa

Detalles Bibliográficos
Autores principales: Mastronuzzi, Angela, Colafati, Giovanna Stefania, Carai, Andrea, D’Egidio, Maria, Fabozzi, Francesco, Del Bufalo, Francesca, Villani, Maria Felicia, Del Baldo, Giada, Vennarini, Sabina, Canino, Costanza, Di Giannatale, Angela, Tomà, Paolo, Garganese, Maria Carmen, De Ioris, Maria Antonietta
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777007/
https://www.ncbi.nlm.nih.gov/pubmed/36551734
http://dx.doi.org/10.3390/cancers14246249
_version_ 1784855998681317376
author Mastronuzzi, Angela
Colafati, Giovanna Stefania
Carai, Andrea
D’Egidio, Maria
Fabozzi, Francesco
Del Bufalo, Francesca
Villani, Maria Felicia
Del Baldo, Giada
Vennarini, Sabina
Canino, Costanza
Di Giannatale, Angela
Tomà, Paolo
Garganese, Maria Carmen
De Ioris, Maria Antonietta
author_facet Mastronuzzi, Angela
Colafati, Giovanna Stefania
Carai, Andrea
D’Egidio, Maria
Fabozzi, Francesco
Del Bufalo, Francesca
Villani, Maria Felicia
Del Baldo, Giada
Vennarini, Sabina
Canino, Costanza
Di Giannatale, Angela
Tomà, Paolo
Garganese, Maria Carmen
De Ioris, Maria Antonietta
author_sort Mastronuzzi, Angela
collection PubMed
description SIMPLE SUMMARY: Central nervous system (CNS) metastatic spread in neuroblastoma (NB) is rare and occurs more often at relapse/progression. In this retrospective study, we reviewed the CNS imaging of all the patients treated at the Bambino Gesù Children Hospital over a 25-year period. CNS metastasis in NB is confirmed to be rare, occurring in 4.7% of patients, and associated with advanced disease and bone skull involvement. In the last decade, the involvement of CNS at relapse has been observed more frequently, supporting the rising concern of the impact of immunotherapy in the pattern of relapse in high risk (HR) NB. Further studies are needed to confirm a higher CNS relapse risk in the immunotherapy era as well as the need for including CNS imaging in follow-up. ABSTRACT: Central nervous system (CNS) metastatic spread in neuroblastoma (NB) is rare and occurs more often at relapse/progression. We report on CNS involvement in high risk (HR) NB over 25 years. For this retrospective study, we reviewed the CNS imaging of all the patients treated at Bambino Gesù Children Hospital from 1 July 1996 to 30 June 2022. A total of 128 patients with HR NB were diagnosed over 26 years. Out of 128 patients, CNS metastatic spread occurred in 6 patients: 3 patients presented a metastatic spread at diagnosis, while in 3 patients, CNS was involved at relapse. Overall, the rate of occurrence of CNS spread is 4.7% with the same distribution at diagnosis and at relapse, namely 2.3%. Interestingly, CNS spread at diagnosis was observed only before 2012, whereas CNS was observed at relapse only after 2012, in the immunotherapy era. CNS metastases presented similar imaging features at diagnosis and at relapse, with a peculiar hemorrhagic aspect and mainly hemispheric localization in patients with bone skull involvement at the time of diagnosis. The outcome is dismal, and 3 out of 6 patients died for progressive disease.
format Online
Article
Text
id pubmed-9777007
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97770072022-12-23 Central Nervous System Metastasis in Neuroblastoma: From Three Decades Clinical Experience to New Considerations in the Immunotherapy Era Mastronuzzi, Angela Colafati, Giovanna Stefania Carai, Andrea D’Egidio, Maria Fabozzi, Francesco Del Bufalo, Francesca Villani, Maria Felicia Del Baldo, Giada Vennarini, Sabina Canino, Costanza Di Giannatale, Angela Tomà, Paolo Garganese, Maria Carmen De Ioris, Maria Antonietta Cancers (Basel) Article SIMPLE SUMMARY: Central nervous system (CNS) metastatic spread in neuroblastoma (NB) is rare and occurs more often at relapse/progression. In this retrospective study, we reviewed the CNS imaging of all the patients treated at the Bambino Gesù Children Hospital over a 25-year period. CNS metastasis in NB is confirmed to be rare, occurring in 4.7% of patients, and associated with advanced disease and bone skull involvement. In the last decade, the involvement of CNS at relapse has been observed more frequently, supporting the rising concern of the impact of immunotherapy in the pattern of relapse in high risk (HR) NB. Further studies are needed to confirm a higher CNS relapse risk in the immunotherapy era as well as the need for including CNS imaging in follow-up. ABSTRACT: Central nervous system (CNS) metastatic spread in neuroblastoma (NB) is rare and occurs more often at relapse/progression. We report on CNS involvement in high risk (HR) NB over 25 years. For this retrospective study, we reviewed the CNS imaging of all the patients treated at Bambino Gesù Children Hospital from 1 July 1996 to 30 June 2022. A total of 128 patients with HR NB were diagnosed over 26 years. Out of 128 patients, CNS metastatic spread occurred in 6 patients: 3 patients presented a metastatic spread at diagnosis, while in 3 patients, CNS was involved at relapse. Overall, the rate of occurrence of CNS spread is 4.7% with the same distribution at diagnosis and at relapse, namely 2.3%. Interestingly, CNS spread at diagnosis was observed only before 2012, whereas CNS was observed at relapse only after 2012, in the immunotherapy era. CNS metastases presented similar imaging features at diagnosis and at relapse, with a peculiar hemorrhagic aspect and mainly hemispheric localization in patients with bone skull involvement at the time of diagnosis. The outcome is dismal, and 3 out of 6 patients died for progressive disease. MDPI 2022-12-19 /pmc/articles/PMC9777007/ /pubmed/36551734 http://dx.doi.org/10.3390/cancers14246249 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mastronuzzi, Angela
Colafati, Giovanna Stefania
Carai, Andrea
D’Egidio, Maria
Fabozzi, Francesco
Del Bufalo, Francesca
Villani, Maria Felicia
Del Baldo, Giada
Vennarini, Sabina
Canino, Costanza
Di Giannatale, Angela
Tomà, Paolo
Garganese, Maria Carmen
De Ioris, Maria Antonietta
Central Nervous System Metastasis in Neuroblastoma: From Three Decades Clinical Experience to New Considerations in the Immunotherapy Era
title Central Nervous System Metastasis in Neuroblastoma: From Three Decades Clinical Experience to New Considerations in the Immunotherapy Era
title_full Central Nervous System Metastasis in Neuroblastoma: From Three Decades Clinical Experience to New Considerations in the Immunotherapy Era
title_fullStr Central Nervous System Metastasis in Neuroblastoma: From Three Decades Clinical Experience to New Considerations in the Immunotherapy Era
title_full_unstemmed Central Nervous System Metastasis in Neuroblastoma: From Three Decades Clinical Experience to New Considerations in the Immunotherapy Era
title_short Central Nervous System Metastasis in Neuroblastoma: From Three Decades Clinical Experience to New Considerations in the Immunotherapy Era
title_sort central nervous system metastasis in neuroblastoma: from three decades clinical experience to new considerations in the immunotherapy era
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777007/
https://www.ncbi.nlm.nih.gov/pubmed/36551734
http://dx.doi.org/10.3390/cancers14246249
work_keys_str_mv AT mastronuzziangela centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera
AT colafatigiovannastefania centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera
AT caraiandrea centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera
AT degidiomaria centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera
AT fabozzifrancesco centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera
AT delbufalofrancesca centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera
AT villanimariafelicia centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera
AT delbaldogiada centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera
AT vennarinisabina centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera
AT caninocostanza centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera
AT digiannataleangela centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera
AT tomapaolo centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera
AT garganesemariacarmen centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera
AT deiorismariaantonietta centralnervoussystemmetastasisinneuroblastomafromthreedecadesclinicalexperiencetonewconsiderationsintheimmunotherapyera